Document:

EX-10.1

 Exhibit 10.1 

SEVERANCE AGREEMENT AND RELEASE 

THIS SEVERANCE AGREEMENT AND RELEASE (the “Agreement”) is entered into by and between FGL Holdings, including all of its past
and present parents, subsidiaries, affiliates and related entities (collectively, the “Employer”), and Christopher J. Littlefield (“Executive”). 

WHEREAS, Executive’s employment with the Employer in accordance with the terms of the Employment Agreement, dated May 6, 2015,
between the Employer and Executive (the “Employment Agreement”) has terminated, and Executive and the Employer wish to resolve all outstanding matters pertaining to Executive’s employment and intend that this termination be
accomplished in a positive spirit and in the interest of goodwill between them. 
 NOW THEREFORE, in consideration of the promises and
covenants contained herein, Executive and the Employer agree as follows: 
 1. Conclusion of Executive’s Employment. Executive
and Employer hereby mutually agree that Executive’s employment with the Employer will terminate, effective as of December 19, 2018 (the “Separation Date”). Effective as of the Separation Date, Executive automatically
resigns from (i) any and all positions that Executive holds with the Employer and (ii) the Board of Directors of FGL Holdings and all committees thereof (and, if applicable, from the board of directors (and any committees thereof) of any
affiliate of FGL Holdings) to the extent Executive is then serving thereon. The form of acknowledgement of such resignation is set forth on Exhibit A and Executive agrees to execute any documents reasonably required to effectuate the
foregoing. The Employer will provide Executive with an advance copy of any press release, investor talking points or other materials that the Employer intends to use regarding the announcement of Executive’s termination of employment and will
consider incorporating any reasonable comments provided by Executive with respect to such press release or other materials. Capitalized terms used but not defined herein shall have the meaning set forth in the Employment Agreement. Except for the
obligations undertaken by the Employer in this Agreement, the Employer shall have no further obligation to Executive. 
 2. Separation
Benefits and IRC Section 409A Compliance. 
  

	 	(a)	 In exchange for execution of this Agreement, Executive shall be entitled to the following payments and
benefits: 

 (i) the Accrued Obligations, payable within thirty (30) day of the Separation Date; 

(ii) an amount equal to $1,100,000 in full satisfaction of Executive’s annual bonus for 2018 (based on actual performance
for 2018), payable no later than January 31, 2019; 
 (iii) $1,288,461.54, payable in a cash lump sum on the first
regularly scheduled payroll date of the Employer following the date on which this Agreement becomes effective; 

 (iv) $1,911,538.46, which represents two (2) times the sum of
Executive’s Base Salary and Target Bonus, less any amounts payable under Paragraph 2(a)(iii) hereof, payable in accordance with the Employer’s normal payroll practices as set forth on Schedule 1 hereto, which such schedule
incorporates the six (6) month delay of payments in accordance with Section 409A of the Internal Revenue Code; 

(v) Executive acknowledges and agrees that the options held by Executive pursuant to those certain Non-Statutory Stock Option Agreements, each dated as of May 15, 2018 (the “Option Agreements”) have no value as of the date hereof. As a gesture of goodwill, the Board shall provide Executive
with a discretionary, cash lump sum payment of $500,000, payable within sixty (60) days following the Separation Date. For the avoidance of doubt, all options issued pursuant to the Option Agreements shall be forfeited as of the Separation
Date; and 
 (vi) A cash payment equal to the actual amount of attorneys’ fees incurred by Executive in connection with
the review, negotiation, drafting and execution of this Agreement and any related arrangements in an amount of up to $50,000, subject to Executive providing the Employer with reasonable documentation of such fees. 

For the avoidance of doubt, (i) the payments set forth in this Agreement will continue to be provided to Executive’s beneficiaries
in the event of his death and (ii) Executive is not required to secure other employment or otherwise take any actions to mitigate the amount of the payments payable hereunder and in no event will any amounts payable to Executive in respect of
any future employment or other service with a third party offset or otherwise reduce the amounts payable to Executive under this Agreement.     

The parties intend that the payments and benefits to which Executive could become entitled in connection with a termination of employment
shall comply with or meet an exemption from Section 409A of the Internal Revenue Code. In this regard, notwithstanding anything in this Agreement to the contrary, all cash amounts that become payable under this Agreement shall be paid within
the “short-term deferral” period described in Section 1.409A-l(b)(4) of the Treasury Regulations, shall qualify for the exception for “separation pay” set forth in Section 1.409A-l(b)(9) of the Treasury Regulations or another exception, or shall comply with Section 409A of the Internal Revenue Code. Payments subject to Section 409A of the Internal Revenue Code
that are due upon termination of employment shall be made only upon “separation from service” within the meaning of Section 409A(a)(2)(A)(i) of the Internal Revenue Code, and shall be subject to the
6-month payment delay described in Section 409A(a)(2)(B)(i) of the Internal Revenue Code if Executive is a “specified employee” as described therein. In the event that it is determined that the
terms of this Agreement do not comply with Section 409A of the Internal Revenue Code, the parties will negotiate reasonably and in good faith to amend the terms of this Agreement so that it complies (in a manner that preserves the economic
value of the payments and benefits to which Executive may become entitled without material increased cost to the Company) so that payments are made within the time period and in a manner permitted by the applicable Treasury Regulations. Executive
shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on or for the account of Executive in connection with this Agreement (including any taxes and penalties under Section 409A of the Code),
and neither the Employer or any of its affiliates shall have any obligation to indemnify or otherwise hold Executive (or any beneficiary) harmless from any or all of such taxes or penalties. 

  
 2 

 3. Return of Property. Within forty-eight (48) hours of the Separation Date,
Executive shall return all Employer property, including all computers, blackberries, other personal data devices, phones, credit cards, keys, and other property of the Employer that are in Executive’s possession or control, to the Employer on
or before the Separation Date and hereby represents compliance with this Paragraph. Specifically, Executive covenants that, no later than forty-eight (48) hours following the Separation Date, Executive returned to the Employer, in good order
and condition, any and all books, records, lists, and other written, typed, printed, or electronically stored material (including, but not limited to, computer disks and customized computer programs), or any other information of any kind deemed by
the Employer to be confidential and/or proprietary, whether furnished by the Employer, or prepared by Executive, that contains any information relating to the business of the Employer, and Executive covenants that Executive has not and will not
retain copies of those materials, nor will Executive retain electronically stored data containing such information. Notwithstanding anything set forth in this Agreement to the contrary, Executive shall be permitted to retain (i) his
Employer-provided MacBook Air laptop computer, provided that Executive make the computer available to Employer personnel to remove selected Confidential Information and other business-related files from such computer and (ii) his list of
business and personal contacts that are maintained on the Employer’s servers or other Employer devices. 
 4. General Release.
Executive hereby irrevocably discharges and releases the Employer, its officers, directors, employees, agents, predecessors, successors and assigns, and all other persons, Major Shareholders (as defined below), corporations, partnerships,
affiliates, or other entities acting on its behalf (collectively, “Released Parties”), from any and all past, present, or future grievances, claims, demands, debts, defenses, actions, or causes of action (including, but not limited
to, breach of contract, defamation, intentional infliction of emotional distress, harassment, battery, or any other cause of action arising under common law, tort, or contract), covenants, contracts, agreements, promises, obligations, damages, or
liabilities of whatever kind or nature, known or unknown, including, but not limited to, any claim of employment discrimination arising under Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans With Disabilities
Act, the Family and Medical Leave Act of 1993 (“FMLA”), 42 U.S.C. §§ 1981, 1985(3), and 1986, the Employee Retirement Income Security Act of 1974, the Age Discrimination In Employment Act (“ADEA”), and/or
any other federal or state statute or common law prohibiting employment discrimination that Executive now has, has had, or may have, whether the same be at law, in equity, or mixed, in any way arising from or relating to the termination of
Executive’s employment with the Company or any other act, omission, failure to act, occurrence, or transaction occurring before the date hereof, it being expressly understood by Executive that, by the execution of this Agreement, Executive has
given the Employer a general release of any and all such claims Executive may have against the Employer. For purposes of this Agreement, “Major Shareholders” means Blackstone Tactical Opportunities Fund II, L.P., CC Capital
Management LLC, Chinh Chu, Bill Foley, Fidelity National Financial, Inc. and their respective affiliates, successors and assigns. This is a general release and Executive expressly acknowledges that this general release includes, but is not limited
to, any claims arising out of or related to Executive’s employment with the Company and Executive’s separation therefrom. 

  
 3 

 By signing this Agreement, Executive expressly acknowledges and represents that:
(i) Executive suffered no injuries or occupational diseases arising out of or in connection with Executive’s employment with the Employer; (ii) Executive received all wages to which Executive was entitled, including all commission
payments; (iii) Executive received all leave to which Executive was entitled under the FMLA; and (iv) Executive is not aware of any facts or circumstances constituting a violation of the FMLA, the FLSA, or any applicable state wage payment
act. 
 Executive expressly states, understands, intends, and agrees that, to the fullest extent permitted by law, this Agreement forever
precludes Executive from bringing, instituting, maintaining, further pursuing, or participating in any lawsuit against the Released Parties for any causes or claims released in this Paragraph 4, other than a lawsuit to challenge this
Agreement’s compliance with the Older Workers Benefit Protection Act (“OWBPA”). Executive represents and agrees that he has not, by himself or on his behalf, instituted, prosecuted, filed, or processed any litigation, claims or
proceedings against the Released Parties, nor has he encouraged or assisted anyone to institute, prosecute, file, or process any litigation, claims or proceedings against the Released Parties. Nothing in this Paragraph 4 shall release or impair
(i) any claim or right that may arise after the date of this Agreement; (ii) any vested benefits under a 401(k) plan or other Employer benefit plan on or prior to the Separation Date; (iii) any claim or right Executive may have
pursuant to indemnification, advancement, defense, or reimbursement pursuant to any applicable D&O policies, any similar insurance policies, the Amended and Restated Memorandum and Articles of Association, applicable law or otherwise;
(iv) any claim which by law cannot be waived; or (v) any rights that Executive may have with respect to any investments Executive has made in any funds relating to The Blackstone Group L.P. or any of its affiliates, subsidiaries or other
related entities. Nothing in this Agreement is intended to prohibit or restrict Executive’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal
administrative body or government agency that is authorized to enforce or administer laws related to employment; provided that Executive hereby waives the right to recover any monetary damages or other relief against any Released Parties;
provided, however, that nothing in this Agreement shall prohibit Executive from receiving any monetary award to which Executive becomes entitled pursuant to Section 922 of the Dodd-Frank Wall Street Reform and Consumer Protection
Act. 
 5. [Intentionally Omitted]  

6. Conditions Precedent. The performance by the Employer of the obligations imposed upon it by this Agreement is expressly conditioned
upon Executive delivering a signed copy of this Agreement to the Employer. 
 7. Discovery of New Facts. Executive acknowledges that
Executive may, following the date hereof, discover facts different from or in addition to what Executive now knows or believes to be true with respect to the matters released herein or set forth herein, and Executive agrees that the release
contained herein shall be and will remain effective in all respects notwithstanding such different or additional facts. It is intended hereby that Executive fully and forever settles and releases all such matters and all claims relative thereto that
now exist, may now exist, or heretofore have existed relating to Executive’s employment with the Employer. 

  
 4 

 8. Adequate Investigation. Executive represents that Executive has made such
investigation of the facts pertaining to this Agreement as Executive deems necessary, and in executing this Agreement, Executive assumes the risk of mistake with respect to such facts. This Agreement is intended to be final and binding upon
Executive, regardless of any claims of mistake. 
 9. Protection of Business. 

(a) Covenants. The provisions of Section 9 (Further Covenants) of the Employment Agreement are hereby incorporated
into this Agreement and shall continue to apply in accordance with their terms. 
 (b)
Non-Disparagement. 
 (i) Executive shall not disparage, portray in a
negative light or make any statement which would be harmful to, or lead to unfavorable publicity for, the Employer, or any of its current or former directors, officers or employees, including, without limitation, in any and all interviews, oral
statements, written materials, electronically displayed materials and materials or information displayed on internet or internet-related sites; provided, however, that this paragraph does not apply to the extent Executive is making truthful
statements when required by law or by order of a court or other legal body having jurisdiction or when responding to a written inquiry from any governmental or regulatory organization. 

(ii) Employer shall instruct (A) Blackstone Tactical Opportunities Fund II, L.P., CC Capital Management LLC and Fidelity
National Financial, Inc. and (B) Employer’s senior officers and directors not to, disparage, portray in a negative light, or make any statement which would be harmful to or lead to unfavorable publicity for, Executive, including,
without limitation, in any and all interviews, oral statements, written materials, electronically displayed materials and materials or information displayed on internet or internet-related sites; provided, however, that this paragraph does not apply
to the extent the Employer or any other person or entity listed in this paragraph is making truthful statements when required by law or by order of a court or other legal body having jurisdiction or when responding to a written inquiry from any
governmental or regulatory organization. 
 (c) Remedies. Executive acknowledges that Employer will suffer
irreparable injury should Executive breach any of the provisions of this Paragraph 9, including those provisions incorporated by reference into this Paragraph 9. Employer shall be entitled to injunctive or other equitable relief because of
irreparable injury and damage caused by a breach of this Paragraph 9, including any provision incorporated by reference into this Paragraph 9. The existence of this right shall not preclude any other rights or remedies at law or in equity that
Employer may have, including monetary relief. This right to injunctive relief shall include the right to both preliminary and permanent injunctions, without the necessity of Employer posting any bond. Executive waives the right to assert a breach of
contract or other alleged wrong by Employer, other than an alleged breach by the Employer of its obligations under Section 8(a) (Death or Disability), 8(c) (Involuntary Termination without Cause, or Termination with Good Reason), or 9(g) (Non-Disparagement) of the Employment Agreement, as a defense to a claimed violation of any provision of this Paragraph 9 or provision incorporated by reference into this Paragraph 9. 

  
 5 

 (d) Whistleblower Protection. Notwithstanding anything to the
contrary contained herein, no provision of this Agreement shall be interpreted so as to impede the Executive (or any other individual) from reporting possible violations of federal law or regulation to any governmental agency or entity, including,
but not limited to, the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or making other disclosures under the whistleblower provisions of federal law or regulation. The Executive does
not need the prior authorization of the Employer to make any such reports or disclosures and the Executive shall not be required to notify the Employer that such reports or disclosures have been made. 

10. Fully-Inclusive Agreement. Executive represents that Executive has not relied on any other oral or written representations of any
kind made by any person in connection with Executive’s decision to sign this Agreement. This Agreement contains the entire agreement between Executive and the Employer with regard to the matters set forth herein, and this Agreement supersedes
any and all prior agreements, contracts, understandings, discussions, or negotiations, whether oral or written, express or implied, between the parties with respect to the subject matter hereof, except for the provisions of the Employment Agreement
which survive in accordance with its terms. 
 11. Binding Agreement. This Agreement is binding upon and for the benefit of Executive
and his heirs, executors, administrators, and successors, wherever the context requires or admits. 
 12. No Transfer of Rights.
Executive represents that Executive has not assigned or transferred, or purported to assign or transfer, to any person, firm, corporation, or other entity whatsoever any of the claims, demands, or causes of action released in Paragraph 4. Executive
agrees to indemnify and hold harmless the Employer against any claim, demand, debt, obligation, liability, cost, expense, right of action, or cause of action based on, arising out of, or connected with any such transfer or assignment, or purported
transfer or assignment, including attorneys’ fees. 
 13. No Admission of Liability. This Agreement is not intended to be, nor
will it be alleged to constitute, evidence or an admission by the Employer of any liability, omission, or wrongdoing of any kind whatsoever, nor shall this Agreement be offered or received into evidence or otherwise filed or lodged in any proceeding
against the Employer, except as may be necessary to prove the terms of this Agreement or to enforce the same. 
 14. Severability and
Reformation. If any provision or any portion of any provision of this Agreement is held to be invalid or unenforceable, the parties hereto expressly agree and authorize the court to modify or sever such provision or portion thereof so as to
render such provision valid and enforceable to the maximum extent lawfully permissible. 
 15. Miscellaneous. This Agreement embodies
the entire agreement and understanding between the parties hereto with respect to the subject matters hereof and may not be changed, waived, discharged, or terminated unless agreed to by both parties and only by an instrument in writing, signed by
both parties. The use of any tense or conjugation includes all tenses and conjugations. This Agreement shall be construed in accordance with and governed by the laws of the State of Iowa, without reference to the principles of conflicts of laws.

  
 6 

 16. Cooperation With Employer. Executive agrees that he will cooperate with the
Employer, its agents, and its attorneys with respect to any matters in which Executive was involved during Executive’s employment with the Employer or about which Executive has information, and will provide upon request from the Employer all
such information or information about any such matter. 
 17. Enforcement. The provisions set forth in Sections 9(m) and 10 of the
Employment Agreement regarding injunctive relief and arbitration are hereby incorporated by reference and shall apply for purposes of this Agreement. 

18. Effectiveness. Executive’s execution of this Agreement is effective as of the date set forth below and is not subject to
revocation; provided that this Agreement shall be terminated and void ab initio and Executive’s automatic resignation in Paragraph 1 shall not be given effect if this Agreement is not validly approved by the Employer on or before
December 19, 2018. 
 [Signature Page Follows] 

  
 7 

 IN WITNESS WHEREOF, the parties have executed this Agreement with the intention of
making this a document under seal. 
 THIS IS A KNOWING AND VOLUNTARY WAIVER AND RELEASE OF ALL LEGAL CLAIMS THAT EXECUTIVE MAY POSSESS. EXECUTIVE IS
INSTRUCTED TO READ THE AGREEMENT CAREFULLY BEFORE SIGNING. 
  

			
	 /s/ Christopher J. Littlefield
	  	  

		
	 Christopher J. Littlefield
	  	 Date: December 19, 2018

		
	 FGL HOLDINGS
	  	
		
	 By: /s/ Eric Marhoun
	  	  

		
	 Name: Eric Marhoun
 Title: Executive Vice
President, General
 Counsel and Secretary
	  	 Date: December 19, 2018

 EXHIBIT A 

Resignation Acknowledgement Letter 

December 19, 2018 
 The
undersigned hereby confirms that he irrevocably resigned from any and all positions he may have held as an officer, director or manager of FGL Holdings and any of its subsidiaries and affiliates (the “Company Group”), effective as
of December 19, 2018. The undersigned’s resignation is irrevocable and is effective without the need for acceptance or any further action by any member of the Company Group. 

 

	
	  

	
	 Name: Christopher J. Littlefield

 SCHEDULE 1 

Payment Schedule 
 The payments
referenced in Section 2(a)(iv) of the Agreement shall be paid to Executive as follows: 
 1. June 27, 2019: $984.615.36 

2. July 11, 2019: $123,076.92 
 3. July 25, 2019:
$123,076.92 
 4. August 8, 2019: $123,076.92 
 5.
August 22, 2019: $123,076.92 
 6. September 5, 2019: $123,076.92 

7. September 19, 2019: $123,076.92 
 8. October 3, 2019:
$123,076.92 
 9. October 17, 2019: $65,384.66EX-10.1

 Exhibit 10.1 

December 18, 2018 
 Melinta Therapeutics, Inc. 

300 George Street 
 Suite 301 

New Haven, Connecticut 06511 
  

	Re:	 Financing Commitment 

Ladies and Gentlemen: 
 Melinta Therapeutics, Inc. (the
“Borrower”) has requested that Vatera Healthcare Partners LLC (“VHP”) and Vatera Investment Partners LLC (“VIP” and, collectively with VHP, the “Initial Lenders”) provide the
Borrower with an up to $135,000,000 senior subordinated convertible loan facility (the “Facility”) on the terms and subject to the conditions set forth in Exhibit A hereto (the “Term Sheet”). Defined terms used but
not defined herein shall have the meanings given thereto in the Term Sheet. 
 1. Commitment. VHP is pleased to inform you of its
several, and not joint, commitment to provide up to $100,000,000 of the Facility and VIP is pleased to inform you of its several, and not joint, commitment to provide $35,000,000 of the Facility (such commitments, collectively, the
“Commitment”). Notwithstanding anything herein to the contrary, the aggregate liability of the Initial Lenders under this letter shall at no time exceed the aggregate amount of the Commitment. For the avoidance of doubt, the
obligation of the Initial Lenders (or their respective successors and permitted assigns) to fund the initial Loans on or after the Closing Date is subject in all respects to the conditions set forth under the heading “Conditions Precedent to
Effectiveness and Initial Loans” in the Term Sheet and the obligation to fund subsequent Loans is subject in all respects to the conditions set forth under the heading “Conditions Precedent to Subsequent Loans” in the Term Sheet. 

2. Termination. The Initial Lenders’ obligation hereunder to enter into the Loan Documents and fund the initial Loans on or after
the Closing Date shall terminate automatically and immediately upon the earliest to occur of (i) the effectiveness on the Closing Date of the Loan Documents in accordance with the Term Sheet, at which time the respective commitments of the
Initial Lenders hereunder shall be replaced with the respective commitments of the Initial Lenders under the Loan Documents, (ii) February 15, 2019 and (iii) the date that a third party acquires all of the capital stock of the Company
through merger, purchase or otherwise. Upon such termination pursuant to this Section 2, the Initial Lenders shall not have any further obligation or liability hereunder with respect to the Commitment, provided,
however that notwithstanding such termination, Sections 4, 5, 6, 7, 8 and 12 shall survive such termination. Notwithstanding any provision hereof to the contrary, the provisions of the Term Sheet set
forth under “Right to Fund” and “Exit Fees” shall become effective immediately upon the effectiveness of this letter (whether or not the Loan Documents are executed) and shall remain effective notwithstanding the termination of
this letter (unless expressly replaced by provisions of the Loan Documents providing for the rights set forth therein) or the Commitment. 

3. Assignment. Subject to applicable securities laws, each Initial Lender may assign all or a portion of its obligation to fund the
Commitment to another Initial Lender, to one or more affiliated investment funds or to other co-investors (which co-investors may include, for the avoidance of doubt,
third party investors that are not affiliated with such Initial Lender or its affiliates) without the consent of the Borrower, but no such assignment (other than to another Initial Lender or affiliate of an Initial Lender) shall relieve any such
Initial Lender of its obligations hereunder. 

 4. No Third Party Beneficiaries. Except to the extent set forth in
Section 5, this letter shall be binding solely on, and inure solely to the benefit of, the parties hereto and their respective successors and permitted assigns, and nothing set forth in this letter, express or implied,
shall be construed to confer upon or give to any person or entity, other than the parties hereto and their respective successors and permitted assigns, any benefits, rights or remedies under or by reason of, or any rights to enforce, the Commitment
or any provisions of this letter. 
 5. Limited Recourse; Enforcement; Indemnity. 

(a) Notwithstanding anything that may be expressed or implied in this letter or any document or instrument delivered in connection herewith,
the Borrower, by its acceptance of the benefits of the Commitment provided herein, covenants, agrees and acknowledges (i) that no person or entity other than the Initial Lenders (and their respective successors and permitted assigns) shall have
any obligation hereunder or in connection with the transactions contemplated hereby, (ii) in no event shall the Borrower seek, and the Borrower shall cause each of its affiliates not to seek, any special, exemplary, consequential, indirect or
punitive damages, or damages arising from loss of profits, business opportunities or goodwill, diminution in value or any other similar losses or damages, whether at law, in equity, in contract, in tort or otherwise, against any Initial Lender or
any Specified Person (as defined below) (the “Non-Prohibited Claims”), and (iii) that, notwithstanding that an Initial Lender may be, or any of its successors and permitted assigns may
be, a corporation, limited liability company or similar business entity, the Borrower shall have no right of recovery against, and no recourse shall be had against, and no personal liability shall attach to, any of the former, current or future
direct or indirect equity holders, controlling persons, stockholders, directors, officers, employees, agents, general or limited partners, managers, members, affiliates, attorneys or other representatives of such Initial Lender or any of such
Initial Lender’s successors or assigns or any former, current or future director, officer, employee, direct or indirect equity holder, equity or other financing source, portfolio company, management company, controlling person, agent, general
or limited partner, manager, member, stockholder, affiliate, attorney or other representative or successor or assign of any of the foregoing (together with any person or entity to whom any of the foregoing has assigned its obligations hereunder in
accordance with the terms hereof, a “Specified Person” and together, the “Specified Persons”), hereunder or under any documents or instruments delivered in connection herewith or in respect of any oral
representations made or alleged to have been made in connection herewith or therewith, whether by or through attempted piercing of the corporate (or limited liability company or limited partnership) veil, by or through a proceeding (whether at law,
in equity, in contract, in tort or otherwise) by or on behalf of the Borrower against any Specified Person, by the enforcement of any assessment or by any legal or equitable proceeding, by virtue of any applicable law, or otherwise, except, for the
avoidance of doubt, for its rights to recover from the Initial Lenders and their respective successors and permitted assigns (but not any other person or entity) under and to the extent provided in this letter and any other claims that are Non-Prohibited Claims; it being agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any Specified Person for any obligations of the Initial
Lenders or any of their respective successors or permitted assigns under this letter or any documents or instruments delivered in connection herewith, in respect of any transaction contemplated hereby or in respect of any representations made or
alleged to have been made in connection herewith or therewith or for any claim (whether at law, in equity, in contract, in tort or otherwise) based on, in respect of, or by reason of such obligations or their creation. 

  
 2 

 (b) Regardless of whether the Closing Date occurs, you agree to (a) indemnify, defend
and hold the Initial Lenders and each of their officers, directors, managers, members, employees and agents (collectively, “Related Parties”) (each, an “Indemnified Person”), harmless from and against all losses,
disputes, claims, investigations, litigation, proceedings, and related reasonable and documented out-of-pocket expenses (but limited to, in the case of attorneys’
fees, the reasonable and documented out-of-pocket fees, charges and disbursements of one external counsel for the Indemnitees, taken as a whole, and, if necessary, one
additional conflicts counsel) to which any Indemnified Person may become subject in connection with this commitment letter, the Term Sheet, the Facility, the use or the proposed use of the proceeds thereof or the transactions contemplated by this
commitment letter or the Term Sheet (each, a “Claim”), regardless of whether such Indemnified Person is a party thereto (and regardless of whether such matter is initiated by or against a third party, you, or any of your
affiliates), and (b) reimburse each Indemnified Person upon demand for all reasonable and documented out-of-pocket expenses (subject to the limitations set forth in
clause (a) with respect to attorneys’ fees) incurred in connection with investigating, preparing to defend or defending, or providing evidence in or preparing to serve or serving as a witness with respect to, any lawsuit, investigation,
claim or other proceeding relating to any of the foregoing (each, an “Expense”); provided that no Indemnified Person shall be entitled to indemnity hereunder in respect of any Claim or Expense to the extent that the same is found by
a final, non-appealable judgment of court of competent jurisdiction to have resulted directly from the gross negligence or willful misconduct of such Indemnified Person or any of its Related Parties. 

(c) Subject to Section 5(d), this letter may only be enforced by the Borrower, and none of the Borrower’s
creditors and no other person or entity that is not a party to this letter shall have any right to enforce this letter or to cause the Borrower to enforce this letter. 

(d) The Specified Persons are express third-party beneficiaries of this Section 5. 

6. Confidentiality. This letter may not be used, circulated, quoted or otherwise referred to in any document (other than any SEC filing
required to be made under applicable law, rule or regulation), except with the written consent of the Initial Lenders; provided, further, that any party hereto may disclose the existence of this letter to the extent required by any
governmental or regulatory authority or as required by applicable law, rule or regulation, so long as the disclosing party (a) promptly notifies the Initial Lenders in reasonable detail of the circumstances giving rise to such required
disclosure, (b) uses its reasonable best efforts to seek to limit such disclosure and maintain the confidentiality of this letter and the terms and conditions hereof and (c) uses its reasonable best efforts to give the Initial Lenders an
opportunity to comment on such disclosure and to incorporate such comments therein. 
 7. Existing Purchase Agreement. Concurrently
with the execution of this letter, the Company and VHP hereby agree that the Purchase Agreement, dated November 19, 2018, by and between the Company and VHP is terminated in all respects, except with respect to Article V (solely to the extent
related to Section 5.1(iii), which, notwithstanding the terms thereof, the Company and VHP agree shall cover the period from and after the date of the Purchase Agreement ) or as otherwise set forth in Section 6.16 thereof. 

  
 3 

 8. Governing Law; Consent to Jurisdiction. 

(a) This letter (and any claim or controversy arising out of or relating to this letter) shall be governed by and construed in accordance with
the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of New York. 

(b) Each party hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any New York state
court, or federal court of the United States of America, in each case sitting in the City, County and State of New York, and any appellate court from any thereof, in any action, suit or proceeding arising out of or relating to this letter or the
transactions contemplated hereby or for recognition or enforcement of any judgment relating thereto, and each party hereby irrevocably and unconditionally: (i) agrees not to commence any such action, suit or proceeding except in such courts;
(ii) agrees that any claim in respect of any such action, suit or proceeding may be heard and determined in such New York state court or, to the extent permitted by applicable Law, in such federal court; (iii) waives, to the fullest extent
it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such action, suit or proceeding in any such New York state or federal court; and (iv) waives, to the fullest extent permitted
by applicable law, the defense of an inconvenient forum to the maintenance of such action, suit or proceeding in any such New York state or federal court. Each party agrees that a final judgment in any such action, suit or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable law. 
 9.
Entire Agreement; Amendments and Waivers. This letter, together with the Loan Documents, constitute the entire agreement between the parties hereto with respect to the subject matter hereof and supersede all prior written or oral and all
contemporaneous oral agreements and understandings between any of the parties hereto with respect to the subject matter hereof and thereof. This letter may not be amended, and no provision hereof waived or modified, except by an instrument signed by
each of the parties hereto. 
 10. Interpretation. The titles and captions in this letter are for reference purposes only, and shall
not in any way define, limit, extend or describe the scope of this letter or otherwise affect the meaning or interpretation of this letter. The words “including” or any variation thereof means “including, without limitation,” and
shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. 

11. Counterparts. This letter may be executed in one or more counterparts for the convenience of the parties hereto, each of which shall
be deemed an original and all of which together will constitute one and the same instrument, and this letter shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties
hereto. Delivery of an executed counterpart of a signature page to this letter by facsimile or electronic transmission shall be effective as delivery of a mutually executed counterpart to this letter. 

12. WAIVER OF JURY TRIAL. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS LETTER IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL 

  
 4 

 
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS LETTER OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT
(A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B) IT UNDERSTANDS AND HAS CONSIDERED
THE IMPLICATIONS OF SUCH WAIVERS, (C) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS LETTER BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 12. 

13. Severability. If any term or other provision of this letter is invalid, illegal or incapable of being enforced by any rule of law or
public policy, all other conditions and provisions of this letter shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any party hereto; provided, however, that this letter may not be enforced without giving effect to the provisions in Sections 1, 2, 3, 4 and 5 of this letter (including by giving effect to any
maximum dollar amounts set forth therein). Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this letter so as to effect the original
intent of the parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. 

  
 5 

 
			
	Very truly yours,
	
	Initial Lenders:
	
	VATERA HEALTHCARE PARTNERS LLC
		
	By:	 	Vatera Holdings LLC, as manager
		
	By:	 	 /s/ Kevin Ferro

		 	Name: Kevin Ferro
		 	Title: CEO
	
	Commitment Amount: $100,000,000
	
	VATERA INVESTMENT PARTNERS LLC
		
	By:	 	Vatera Holdings LLC, as manager
		
	By:	 	 /s/ Kevin Ferro

		 	Name: Kevin Ferro
		 	Title: CEO
	
	Commitment Amount: $35,000,000

  
 6 

			
	Accepted and acknowledged:
	
	The Borrower:
	
	MELINTA THERAPEUTICS, INC.
		
	By:	 	 /s/ John H. Johnson

		 	Name: John H. Johnson
		 	Title: Interim CEO

  
 7 

 Exhibit A 

MELINTA THERAPEUTICS, INC. 

Senior Subordinated Convertible Loans 

Term Sheet 
  

			
	Borrower:	  	Melinta Therapeutics, Inc. (the “Borrower”).
		
	Guarantors:	  	Each of the Borrower’s direct or indirect subsidiaries that guarantees the Borrower’s obligations under the Facility Agreement, dated as of January 5, 2018 (as amended, supplemented or otherwise modified from time to
time, the “Deerfield Facility Agreement”), among the Borrower, certain of its subsidiaries, the lenders parties thereto and Cortland Capital Market Services LLC, as agent (the “Guarantors”).
		
	Lenders:	  	Initially, Vatera Healthcare Partners LLC (“VHP”), Vatera Investment Partners LLC (“VIP”) and certain of their respective affiliates (collectively, “Vatera”), subject to the right
of Vatera to syndicate the Loans to one or more additional lenders (collectively with Vatera, the “Lenders”).
		
	Commitment:	  	A senior subordinated convertible loan facility (the “Facility”) in a committed amount of $135 million.
		
	Availability:	  	Borrowings under the Facility (“Loans”) shall be available on the following schedule:
		
		  	 1.  Subject to the conditions precedent set forth under “Conditions Precedent to
Effectiveness and Initial Loans”, $75 million (but not less than $75 million), of Loans will be drawn in a single draw on the Closing Date. Such Loans shall be provided by VHP (or its permitted assigns).

		
		  	 2.  Subject to the conditions precedent set forth under “Conditions Precedent to
Subsequent Loans”, (a) an additional up to $25 million of Loans may be drawn in a single draw after March 31, 2019, such Loans to be provided by VHP (or its permitted assigns), and (b) an additional up to $35 million of
Loans may be drawn in a single draw after June 30, 2019, such Loans to be provided by VIP (or its permitted assigns).

		
		  	No drawdowns will be permitted after July 10, 2019.
		
	Ranking; Subordination:	  	The obligations under the Facility shall be senior unsecured obligations of the Borrower and each Guarantor and shall be subordinated to the obligations under the Deerfield Facility Agreement pursuant to a subordination agreement
(the “Subordination Agreement”) on terms to be agreed with the lenders thereunder.

			
		
	Exit Fees:	  	A fee of 1% of the aggregate amount of Loans funded under the Facility shall be payable on any repayment or conversion of such funded amount, on the portion of such funded amount so repaid or converted. In the case of conversion,
such fee shall be converted to stock on the same basis as the principal balance of the Loans as set forth below under “Conversion”.
		
		  	In addition, a fee of 3% of the portion of the aggregate committed amount of Loans not funded under the Facility shall be payable on any repayment in full or conversion in full of the Loans. In the case of conversion in full of the
Loans, such fee shall be converted to stock on the same basis as the principal balance of the Loans as set forth below under “Conversion”.
		
	Interest:	  	The Loans will bear interest at a rate equal to 5.0% per annum. Such interest shall be payable in kind, other than a portion thereof in an amount sufficient to cover any income taxes that would otherwise be payable by the Lenders in
respect of “phantom income” on such paid-in-kind interest, which will be payable in cash.
		
	Right to Fund:	  	If (a) the Company has received a bona fide offer from a third party to acquire 19% or more of the capital stock of the Company (whether through merger, purchase or otherwise) and (b) as of the date of such offer the
aggregate amount of Loans funded under the Facility does not equal or exceed $75 million, VHP (or its permitted assignees) shall have the right (but not the obligation) to make a Loan (which Loan shall be convertible in the manner set forth
under “Conversion” below) in an amount up to such unfunded amount (such that the total amount of the Loans funded hereunder is $75 million) prior to the consummation of such transaction.
		
	Interest Payments:	  	Interest will be computed on the basis of a 360-day year for actual days elapsed. Interest paid in kind will be added to the principal balance of the Loans at the end of each fiscal quarter
(and shall bear interest once added to such principal balance). Cash interest will be payable in arrears at the end of each quarter.
		
	Use of Proceeds:	  	The proceeds of the Loans will be used for general corporate purposes, but shall not, without the prior written consent of VHP in its sole discretion, be used to pay all or any portion of any liability in excess of $15 million
in the aggregate.
		
	Term:	  	The maturity date (the “Maturity Date”) will be January 6, 2025.

			
		
	Amortization:	  	None.
		
	Optional Prepayments:	  	To the extent permitted under the Subordination Agreement, the Loans may be prepaid in whole or in part without premium or penalty, subject to the payment of any applicable Call Premium as set forth below, upon 15 business
days’ prior written notice; provided, that no prepayment shall be permitted if the VWAP of the Borrower’s common stock for the five-trading-day period ending on and including the trading day
immediately preceding the giving of such prepayment notice exceeds the Conversion Price. In the event the Borrower elects to pre-pay the Loans, the Lenders shall have the right, prior to such prepayment, to
convert all or a portion of the Loans to be so prepaid (but, for the avoidance of doubt, not including any Call Premium) at the Fundamental Change Conversion Price described below under “Conversion.”
		
	Call Premium:	  	Customary for financings similar to the Facility, which decreases over time to the maturity date.
		
	Mandatory Prepayments:	  	Upon the occurrence of a Change of Control (to be defined consistent with the Deerfield Facility Agreement as amended in accordance with this Term Sheet), the Lenders shall have the right to either convert the Loans (as described
below under “Conversion”) or require payment in full at par plus accrued and unpaid interest.
		
	Conversion:	  	Convertible at the option of each Lender into convertible preferred stock of the Borrower (the “preferred stock”) at a conversion price of $1.60 per share (the “Conversion Price”) as described
below. The preferred stock will be non-participating, convertible preferred stock, with no dividend rights (other than to participate in dividends paid on the common stock (as defined below) on an as-converted basis) or voting rights. The preferred stock will be senior to the common stock upon liquidation (with a liquidation preference equal to the Base Amount (as defined below)) and will be convertible into
common stock of the Borrower at the Conversion Price (i.e., the initial conversion price of the preferred stock will be the same as the then applicable Conversion Price) as described below. The Conversion Price will be subject to adjustments
customary for convertible notes for splits or combinations of, recapitalization or reclassification of, and the payment of dividends on, the Borrower’s common stock, par value $0.01 per share (the “common stock”), as well as
the distribution of rights, options or warrants to all or substantially all holders of common stock at a price less than the five-trading-day VWAP of the common stock, and any tender offer by the Borrower for
common stock at an amount exceeding the five-trading-day VWAP of the common stock; provided that the Conversion Price of the preferred stock shall not be subject to adjustment for any dividends or
distributions in which the preferred

			
		  	stock participates. The issuance of additional shares of common stock or other securities (except for stock dividends on the common stock), including pursuant to employee equity plans, warrants or other exercisable or convertible
securities, shall be excluded from such adjustments. The Conversion Price also will be subject to decrease in the event the Lender converts the Loans in connection with a “fundamental change” (to be defined in a manner customary for
convertible notes), based on a customary make-whole table with inputs relative to either the average of the last reported sale prices of the common stock over the five trading day period ending on and including the trading day immediately preceding
the effective date of the fundamental change (or the date of the prepayment notice, as applicable) or the cash price paid per share of common stock in the transaction (the “Fundamental Change Repurchase Price”); provided that, to
the extent the Conversion Price would be decreased to an amount (the “Floor Price”) that would cause the number of underlying shares of preferred stock or common stock to exceed the amount of the then available authorized shares, the
Company will obtain stockholder approval to increase the number of authorized shares or, absent such approval, the Conversion Price will be decreased to the Floor Amount and the balance of any make-whole amount will be paid in cash rather than
settled in stock. In the event that a conversion during a prepayment period would also be deemed to be in connection with a fundamental change, a holder of the Loans to be converted will be entitled to a single adjustment to the Conversion Price
with respect to the first to occur of the applicable redemption notice date or the effective date of the applicable fundamental change, and the later event will be deemed not to have occurred for purposes of the adjustments.
		
		  	The Loans shall be convertible into a number of shares of preferred stock equal to (i) the aggregate principal amount of such Loans being converted (including any interest paid in kind that has been added to the principal
balance of the Loans at the end of a fiscal quarter), plus any accrued and unpaid interest that is to be paid in kind at the end of the next fiscal quarter but has not yet been so paid, plus the portion of any Exit Fee attributable to the committed
amount of the Loans being so converted (clause (i), collectively, the “Base Amount”), divided by (ii) the then applicable Conversion Price for the Loans. The shares of preferred stock shall be convertible into a number of
shares of common stock equal to (i) the Base Amount (i.e., the liquidation preference of the preferred stock) divided by (ii) the then applicable Conversion Price for the preferred stock.
		
	Documentation:	  	The definitive documentation for the Facility (the “Loan Documents”) shall consist of a credit agreement, one or more guarantee agreements, the Subordination Agreement and other customary documentation for similar
financing transactions, in each case consistent with the terms and conditions set forth herein and otherwise in form and substance satisfactory to the Borrower and Lenders holding a majority of the Commitment (as defined in the Commitment Letter)
(the “Majority Lenders”), who may approve the Loan Documents on behalf of each Lender.

			
		
		  	Representations and warranties, affirmative covenants and events of default shall be substantially similar to those set forth in the Deerfield Facility Agreement and otherwise shall be customary for financing transactions similar to
the Facility.
		
		  	The documentation shall also contain “clear market” provisions, registration rights for the common stock, requirements to list the common stock underlying the loans on Nasdaq, indemnification and other covenants consistent
with (taking into account the character of the loans and the application of the securities laws to convertible instruments) the terms of the existing Purchase Agreement, dated November 19, 2018, with VHP.
		
	Negative Covenants:	  	To be substantially similar to those set forth in the Deerfield Facility Agreement and otherwise to be customary for financing transactions similar to the Facility and to include, without limitation, a prohibition on additional
indebtedness for borrowed money other than purchase money debt and a senior-secured revolving credit facility (the “Permitted Revolver”), in each case to the extent permitted under the Deerfield Facility Agreement as in effect on
the date hereof.
		
	Conditions Precedent to Effectiveness and Initial Loans:	  	The effectiveness of the Facility (the date of such effectiveness, the “Closing Date”) and to the initial funding of the Facility will be subject to conditions precedent that are customary for financings similar
to the Facility including, without limitation, the following:
		
		  	 1.  The Majority Lenders shall have received (a) the Loan Documents, duly
executed and delivered by the parties thereto and (b) such other customary closing documents as the Majority Lenders shall have requested from the Borrower.

		
		  	 2.  The Majority Lenders shall have received a duly executed notice of borrowing at
least 5 business days prior to the proposed date of such borrowing.

		
		  	 3.  In the reasonable judgment of the Majority Lenders, no event or change shall have
occurred that could reasonably be expected to result in a material adverse effect on (a) the business, assets, operations or financial condition of the Borrower and the Guarantors, taken as a whole, or (b) the ability of the Borrower and
the Guarantors, taken as a whole, to perform the obligations under the Loan Documents and/or the Deerfield Facility Agreement.

			
		
		  	 4.  The representations and warranties set forth in the Loan Documents shall be true
and correct in all material respects (or, to the extent qualified by materiality or material adverse effect, in all respects) as of the date of such borrowing and after giving effect thereto (or, to the extent expressly made as of a prior date, such
prior date).

		
		  	 5.  Before giving effect to such funding, no default or event of default shall have
occurred and be continuing, and after giving effect to such funding, no default or event of default shall have occurred and be continuing or reasonably expected to occur under the Loan Documents.

		
		  	 6.  Before giving effect to such funding, no default or event of default shall have
occurred and be continuing, and after giving effect to such funding, no default or event of default shall have occurred and be continuing or reasonably expected to occur under the Deerfield Facility Agreement.

		
		  	 7.  The Closing Date shall have occurred no later than February 15,
2019.

		
		  	 8.  All reasonable and customary expenses required to be reimbursed to the Lenders by
the Borrower shall have been paid in full.

		
		  	 9.  Stockholder approval (i) to increase the Borrower’s authorized share
capital and (ii) to approve the issuance under applicable Nasdaq rules shall have been obtained.

		
		  	 10.  The Borrower’s common stock shall remain listed on Nasdaq.

		
		  	 11.  John Johnson shall be appointed as CEO (as opposed to Interim CEO) of the
Borrower not later than the Closing Date.

		
		  	 12.  The Board shall have approved a
go-forward operating plan, taking into account funding under the Facility, that shall not reasonably be expected to result in a default or event of default under the Loan Documents or the Deerfield Facility
Agreement.

		
		  	 13.  The Deerfield Facility Agreement shall have been modified in a manner reasonably
satisfactory to the Majority Lenders and the Borrower as follows:

		
		  	 a.   The definition of “Change of Control” set forth in
Section 1.1 thereof shall be amended to delete clause (c) thereof, which currently prohibits Vatera from owning 50% or more of the equity interests in the Borrower on a fully diluted basis. Clause (b) thereof will be amended to carve-out VHP, VIP and their respective affiliates from time to time.

			
		
		  	 b.  The definition of “Indebtedness” set forth in Section 1.1 thereof
shall be amended to exclude from Indebtedness the existing obligations under (x) the Agreement and Plan of Merger, dated as of December 3, 2013, among The Medicines Company, Rempex Pharmaceuticals, Inc. and the other parties thereto and
(y) the Purchase and Sale Agreement, dated as of November 28, 2017, between The Medicines Company and Melinta Therapeutics, Inc.

		
		  	 c.   Clause (n) of the definition of “Permitted Indebtedness” set
forth in Section 1.1 thereof shall be waived to the permit the payment of cash interest on the Facility in the amounts set forth under “Interest” and “Interest Payments” above.

		
		  	 d.  Section 5.1(h) thereof shall not require that Borrower’s audited
financial statements for the fiscal year ending December 31, 2018 be delivered without an explanatory paragraph expressing doubt as to the Borrower’s status as a going concern.

		
		  	 e.   Section 5.1(v)(ii) thereof shall be amended to reduce the net sales
covenant set forth therein for all periods after December 31, 2018, by 15%.

		
		  	 14.  The Majority Lenders shall not have become aware of any adverse information, fact
or circumstance with respect to the Borrower and the Guarantors that is inconsistent with the information available to the Majority Lenders on the date of the Commitment Letter in any material respect.

		
		  	 15.  All other aspects of the Loan Documents and the transactions contemplated hereby
shall be acceptable to the Majority Lenders in their sole discretion.

		
		  	Notwithstanding any provision of the Loan Documents, the Commitment Letter or this Term Sheet to the contrary, a determination by the Majority Lenders that any of the conditions precedent set forth under “Conditions Precedent
to Effectiveness and Initial Loans” above, “Conditions Precedent to Subsequent Loans” below or otherwise set forth in the Loan Documents, have been met, or any decision by the Majority Lenders to waive any of such conditions, shall be
binding upon all Lenders.
		
	Conditions Precedent to Subsequent Loans:	  	Subsequent Loans will be subject to the following conditions precedent:

			
		
		  	 1.  The Lenders shall have received a duly executed notice of borrowing at least 10
business days prior to the proposed date of such borrowing.

		
		  	 2.  In the reasonable judgment of the Majority Lenders, no event or change shall have
occurred that could reasonably be expected to result in a material adverse effect on (a) the business, assets, operations or financial condition of the Borrower and the Guarantors, taken as a whole, or (b) the ability of the Borrower and
the Guarantors, taken as a whole, to perform the obligations under the Loan Documents and/or the Deerfield Facility Agreement.

		
		  	 3.  The representations and warranties set forth in the Loan Documents shall be true
and correct in all material respects (or, to the extent qualified by materiality or material adverse effect, in all respects) as of the date of such borrowing and after giving effect thereto (or, to the extent expressly made as of a prior date, such
prior date).

		
		  	 4.  Before giving effect to such funding, no default or event of default shall have
occurred and be continuing, and after giving effect to such funding, no default or event of default shall have occurred and be continuing or reasonably expected to occur under the Loan Documents.

		
		  	 5.  Before giving effect to such funding, no default or event of default shall have
occurred and be continuing, and after giving effect to such funding, no default or event of default shall have occurred and be continuing or reasonably expected to occur under the Deerfield Facility Agreement.

		
		  	 6.  Both before and after giving effect to the funding of the third tranche of the
Loans, the Borrower shall have obtained a Permitted Revolver with respect to which no less than $10 million shall be available for drawing on and after such funding date (without giving effect to any repayment on such date with the proceeds of
the Loans).

		
	Indemnity and Expenses:	  	The Loan Documents will provide customary indemnification and expense reimbursement to the Lenders.
		
	Assignments and Participations:	  	The Loans will be assignable by the Lenders to, and the preferred stock will be transferable to, QIBs or institutional accredited investors (other than competitors). Assignment of the Loans will also be subject to all applicable
securities laws. The shares of preferred stock issuable upon conversion of the Loans, and the shares of common stock issuable upon conversion of the preferred stock, also will bear a customary restricted stock
legend.

			
		
	Voting:	  	Amendments, waivers and other modifications of the Loan Documents will require the prior written consent of the Majority Lenders and VHP.
		
	Governing Law and Jurisdiction:	  	The Loan Documents will provide that the Borrower and the Guarantors will submit to the exclusive jurisdiction and venue of the federal and state courts of the County and State of New York and will waive any right to trial by jury.
New York law will govern the Loan Documents.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]